The good news is that treatment options for lung cancer patients are rapidly improving. In the last two years, more treatments have been approved by the United States Food and Drug Administration (FDA) for the treatment of lung cancer than had been approved in the prior ten years. New and life saving treatments, along with clinical trials, are happening rapidly and LCFA is committed to keeping you up to date on the latest, most hopeful and helpful, information.
from MIT News Bacteria promote lung tumor development, study suggests MIT cancer biologists have discovered a new mechanism that lung tumors exploit to promote their own survival: These tumors alter bacterial populations within the lung, pr…
from OncLive The scope of targeted therapies has extended more in non–small cell lung cancer (NSCLC), especially with the recent FDA approval of larotrectinib (Vitrakvi) for patients with NTRK gene fusions irrespective of the primary tumor…
From Medical Express Molecular profiling to catch lung cancer early The world's first genetic sequencing of precancerous lung lesions could pave the way for very early detection and new treatments, reports a new study led by University Coll…
From MedExpress Lung cancer remains a major cause of mortality across the globe, although we are gaining a deeper understanding of the genetic background behind this disease, including the mutations that promote it. Mutation in the gene EGFR…
How bias in the medical community hurts lung cancer patients. from The Washington Post Not long ago, I was working in a busy teaching hospital’s intensive-care unit, poring over EKGs, examining X-rays and reviewing medication orders. I re…
from EurekAlert University of Colorado Study Patients now living a median 6.8 years: According to the National Cancer Institute, patients diagnosed with non-small cell lung cancer (NSCLC) between the years 1995 and 2001 had 15 percent chan…
From UC San Diego Health State’s long-term, aggressive tobacco control programs cited as primary reason Early adoption of tobacco control efforts in California led to fewer people ever smoking, reduced the amount used by those who do smok…
From Specialty Pharmacy Times Clinical Trial results: First-line immunotherapy combo fails: New study shows that first-line immunotherapy that uses durvalumab (Imfinzi, AstraZeneca) or the combination of durvalumab and tremelimumab failed t…
from Business Wire FDA Approves Atezolizumab in Combination Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) approvedatezolizumab (Tecentriq®), in combination with Avastin® (bevac…
from The Hill Advances in Lung Cancer Treatment Advances in treatment have completely transformed the way that Americans are living with lung cancer, something that was unthinkable even ten years ago. Since 2015, the U.S. Food and Drug Ad…